Aristides Capital LLC Makes New $193,000 Investment in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Aristides Capital LLC bought a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 29,285 shares of the company’s stock, valued at approximately $193,000. Aristides Capital LLC owned 0.09% of Lexeo Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. acquired a new stake in Lexeo Therapeutics in the third quarter worth about $11,307,000. Point72 Asset Management L.P. bought a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at about $3,348,000. Geode Capital Management LLC grew its position in shares of Lexeo Therapeutics by 86.5% during the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after buying an additional 256,635 shares during the period. Privium Fund Management B.V. bought a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $909,000. Finally, Exome Asset Management LLC acquired a new position in Lexeo Therapeutics in the third quarter valued at approximately $797,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Performance

LXEO stock opened at $1.79 on Tuesday. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market cap of $59.42 million, a PE ratio of -0.57 and a beta of 1.52. The business’s 50-day moving average price is $3.74 and its two-hundred day moving average price is $6.23.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.09. As a group, research analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on LXEO. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, March 26th. Leerink Partners decreased their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Royal Bank of Canada cut their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. Finally, Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $22.80.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.